AMRI signs agreement with Australian firm Parnell

AMRI signs agreement with an Australian firm Parnell

2:29 PM, 17th June 2011
AMRI signs agreement with an Australian firm Parnell

 

ALBANY, US: AMRI announced it has signed a development and long term exclusive commercial supply agreement with Parnell Manufacturing Pty Ltd. Under the agreement, AMRI will provide process development, manufacturing and supply of active pharmaceutical ingredients (APIs) to support Parnell’s submission of a New Animal Drug Application (NADA) with the US Food and Drug Administration (FDA) and commercial launch of its veterinary product onto the US market pending regulatory approval. The development and manufacture of this API will take place at AMRI’s facilities in Albany, NY.

“Parnell sought expressions of interest for the development and long term supply of this API from several companies and we are pleased that AMRI was ultimately successful in their tender. This product is an extremely important project for Parnell and the FDA compliant development is paramount to the successful launch,” said Robert Joseph, CEO, Parnell.

© WOC News

 

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


SK Capital Partners recapitalizes Calabrian Corporation

NEW YORK, US: SK Capital Partners announced that it has partnered with Charles Cogliandro, Chief Executive Officer to recapitalize Houston-based Cal ...

Read more
Asahi Kasei launches new mid-term management initiative

The Asahi Kasei Group has launched a new mid-term strategic management initiative, “For Tomorrow 2015,” for the five-year period from fi ...

Read more
Momentive, Zhejiang Xinan joint venture to expand capacity in China

ALBANY, US/JIANDE, CHINA: Momentive Performance Materials Inc and Zhejiang Xinan Chemical Industrial Group announced their joint venture company, Zh ...

Read more
Merck KGaA profit jumps with sales hikes

Total revenues increase 22 per cent to € 2.6 billion Group free cash flow totaled € 645 million 2011 guidance on Group operating result ...

Read more
ICL acquires food ingredients firm in Mexico

  ST LOUIS, US: ICL Performance Products, an operating segment of Israel Chemicals, has signed an agreement to acquire Cosmocel Quimica S.A. de ...

Read more
Wacker reports good start on higher sales volumes

Group sales increases by 21 per cent to € 1.29 billion in Q1 2011 EBITDA grow by 38 per cent to € 351 million Quarterly net income cli ...

Read more